Thelansis

Bipolar Depression Market Outlook Thelansis’s “Bipolar Depression Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Bipolar Depression treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the market’s trajectory? What in...

  Bipolar Depression Market Outlook Thelansis’s “Bipolar Depression Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Bipolar Depression treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Bipolar Depression Overview Bipolar depression is frequently misdiagnosed as unipolar depression due to the overlap in clinical symptoms between these two conditions. Patients may not recognize their ‘high’ periods as illness, leading them to seek assistance only during depressive episodes. As a result, bipolar depression often goes unrecognized for several years, especially in cases of bipolar II disorder, where hypomania episodes can be mistaken ...

Autobahn Therapeutics, a biotech company focused on developing restorative treatments for neuropsychiatric and neuroimmunologic disorders, announced the clearance of an investigational new drug (IND) application by the U.S. FDA. This clearance supports the initiation of a Phase 2 trial of ABX-002 as an adjunctive treatment for patients with bipolar depression. ABX-002 is a highly potent, oral, thyroid hormone beta receptor (TRβ) selective agonist designed to enhance the CNS benefits of thyroid hormone biology and drug concentrations directly in the brain. Publish Date: 22-10-2024   Source: Autobahn Therapeutics Bipolar depression is frequently misdiagnosed as unipolar depression due to the overlap in clinical symptoms between these two conditions. Patients may not recognize their ‘high’ periods as illness, leading them to seek assistance only during depressive episodes. As a result, bipolar depression often goes unrecognized for several years, especially in cases of bipola...

  Bipolar depression is frequently misdiagnosed as unipolar depression due to the overlap in clinical symptoms between these two conditions. Patients may not recognize their 'high' periods as illness, leading them to seek assistance only during depressive episodes. As a result, bipolar depression often goes unrecognized for several years, especially in cases of bipolar II disorder, where hypomania episodes can be mistaken for a return to normal mood after depression. In over 50% of bipolar disorder cases, depression is the initial manifestation of the illness, creating a diagnostic challenge in distinguishing it from unipolar depression. The symptom profile includes psychomotor retardation, 'atypical' features such as increased appetite and excessive sleep (reverse neurovegetative), and sometimes psychotic symptoms. Episodes of bipolar depression tend to be more rapid in onset, more frequent, and shorter in duration than unipolar depression. However, in practice, ther...

 Bipolar depression is frequently misdiagnosed as unipolar depression due to the overlap in clinical symptoms between these two conditions. Patients may not recognize their 'high' periods as illness, leading them to seek assistance only during depressive episodes. As a result, bipolar depression often goes unrecognized for several years, especially in cases of bipolar II disorder, where hypomania episodes can be mistaken for a return to normal mood after depression. In over 50% of bipolar disorder cases, depression is the initial manifestation of the illness, creating a diagnostic challenge in distinguishing it from unipolar depression. The symptom profile includes psychomotor retardation, 'atypical' features such as increased appetite and excessive sleep (reverse neurovegetative), and sometimes psychotic symptoms. Episodes of bipolar depression tend to be more rapid in onset, more frequent, and shorter in duration than unipolar depression. However, in practice, there i...